What Vivitrol Injection Treats: Main Uses and Benefits

This medication is commonly used within two primary therapeutic domains, playing a relevant role in Medication-Assisted Treatment (MAT) for specific substance use disorders. It is indicated for managing opioid dependence and Alcohol Use Disorder (AUD).

---

Key Therapeutic Support

The injection is generally used in clinical settings that involve acute or unstable symptom patterns, such as moderate-to-severe AUD, or following opioid detoxification. This supportive treatment is designed to address symptoms that create noticeable physiological strain, like the intense psychological cravings for alcohol or the rewarding feelings linked to opioid use. By easing these challenging manifestations, the medication may assist with maintaining a sense of stability when symptoms are more noticeable. It provides supportive therapeutic benefit with a consistent effect. This is relevant in contexts involving heightened systemic burden where consistent coverage is necessary.

---

Quick Fact Block

Quick Fact: Symptomatic Support for Pathological Cravings
Symptom Domain	Symptoms related to heightened physiological activity and psychological drive.
Primary Benefit	May provide support that helps ease the overall symptom burden of intense urges.
Clinical Context	Applied during phases when symptoms become more noticeable and may interfere with daily functioning.

Who Can and Cannot Use Vivitrol Injection?

The official regulatory profile for Vivitrol injection establishes strict eligibility requirements, primarily defined by the patient’s opioid status and certain health conditions.

Populations for Whom Use is Allowed

The medication is approved for use in adults 18 years of age and older. Treatment initiation requires that patients must be opioid-free for a recommended minimum of 7 to 10 days prior to the first injection to prevent precipitated opioid withdrawal. For alcohol dependence, patients should not be actively drinking at the time of initial administration.

Populations for Whom Use is Contraindicated

Use is absolutely contraindicated in patients currently receiving opioid analgesics, those with physiologic opioid dependence, and individuals in acute opioid withdrawal. It is also prohibited if a patient has a positive urine screen for opioids or has failed the naloxone challenge test. Patients with acute hepatitis or liver failure must not use the medication, nor should those with a prior hypersensitivity to naltrexone or any component of the diluent.

Age and Condition-Specific Limitations

The safety and effectiveness have not been established for pediatric patients (under 18 years of age). For geriatric patients, no overall differences in safety or effectiveness were observed compared to younger adults. The regulatory label advises caution for patients with moderate to severe renal impairment, and notes that pharmacokinetics have not been evaluated in patients with severe hepatic impairment (Child-Pugh Class C).

Pregnancy and Lactation Status

There is insufficient data in humans regarding use during pregnancy. For lactation, naltrexone and its metabolite are excreted into human milk, and the effect on the breastfed infant is unknown.

Interactions with other medicines and products

This section describes officially documented interaction patterns for naltrexone extended-release, as specified in government regulatory documents.

Pharmacodynamic Interactions and Restrictions

Classification	Interacting Substance/Condition	Restriction / Outcome
Contraindicated	Opioid Analgesics	Formal co-administration prohibition.
Contraindicated	Physiologic Opioid Dependence	Prohibited for use in patients with current dependence, acute withdrawal, or a positive opioid test.
Timing-based Rule	Opioid-Containing Medicines	A minimum 7 to 10-day opioid-free period is required prior to the first dose to prevent the interaction of precipitated withdrawal.
Antagonism	Opioid Cough/Cold/Diarrhea Medicines	The antagonist effect extends to these opioid-containing products.

Pharmacokinetic and Other Interactions

• Acamprosate: Co-administration with naltrexone is documented to increase the systemic exposure of acamprosate, affecting its maximum plasma concentration (C max) and area under the curve (AUC).
• Metabolic Pathway: Official documents state that naltrexone metabolism does not involve the Cytochrome P450 (CYP) system, as clearance is mediated by dihydrodiol dehydrogenase, meaning typical CYP-mediated drug interactions are not expected.
• Alcohol: The product is officially documented to not cause a disulfiram-like reaction upon alcohol consumption.
• Population-Specific Caution: Use is contraindicated in acute hepatitis or liver failure. Caution is advised in patients with renal impairment, though mild insufficiency is documented to have little influence on naltrexone pharmacokinetics.

The regulatory profile is centered on the opioid antagonism, defining strict prohibitions and required timing rules to manage the risk of precipitated withdrawal, complemented by specific pharmacokinetic and population-related interaction constraints.

Vivitrol (Naltrexone) exerts its action through a precise pharmacodynamic mechanism centered on the opioid receptor system, which establishes a continuous and sustained biological effect at the molecular level.

---

Competitive Blockade of the Mu-Opioid Receptor

The primary function of Naltrexone is competitive antagonism, acting directly on opioid receptors in the central and peripheral nervous systems, with the highest affinity for the μ-opioid receptor (μ-MOR). By binding tightly to these receptors, Naltrexone physically occupies the site, which prevents any external opioid substance from interacting with the receptor and triggering its associated signaling cascade. This molecular blockade results in the functional neutralization of the body’s ability to respond to opioids, preventing the subsequent activation of physiological pathways and psychoactive response.

---

Functional Deactivation of Central Reward Signaling

This antagonism critically affects the brain's mesolimbic reward pathway. Opioid activation of μ-MORs typically modulates this circuit, causing a surge in dopamine release in the Nucleus Accumbens. By blocking the μ-MOR signal, Naltrexone interrupts the crucial upstream signal needed to initiate this surge. This functional deactivation of the reward pathway is the mechanism by which the drug prevents the characteristic opioid-induced modulation of reward signaling.

---

⏱️ Sustained Receptor Saturation by Extended-Release System

The medication is formulated as an extended-release suspension, which is a key component of its mechanism. This specialized delivery system facilitates a slow, steady, and continuous release of Naltrexone into the system over approximately four weeks. This sustained release mechanically facilitates the necessary receptor saturation level to maintain the constant and stable competitive antagonism, which is required for the maintenance of the continuous competitive antagonism.

The administration of Vivitrol injection follows specific, fixed requirements defining how the medicine is used in clinical practice.

The standard dose for adults is a single, fixed strength of 380 mg. The medicine is administered exclusively by deep intramuscular (IM) injection into the gluteal muscle, never intravenously or subcutaneously. A key component of the treatment regimen is the dosing schedule, which requires the fixed 380 mg dose to be administered once every four weeks or once a month to ensure sustained systemic coverage. Usage protocols involve alternating the injection site between the buttocks with each subsequent dose to maintain proper administration patterns.

Because the medication is an extended-release suspension, it must be prepared and administered by a healthcare professional (HCP) in a clinical setting; this includes reconstituting the microspheres with the provided diluent just prior to injection. No dose adjustments are specified for patients with mild-to-moderate renal or hepatic impairment. If a dose is missed, it should be given as soon as possible, while strictly observing the minimum interval of four weeks between administrations to avoid improper use patterns.

Research Evidence / Overview of Studies for Vivitrol Injection

The evidence for the extended-release Naltrexone injection comes from official clinical research, primarily randomized controlled trials (RCTs). This overview describes what the research has explored and what studies monitored, without offering clinical advice or personal predictions.

---

Evidence for Use in Alcohol Use Disorder (AUD)

Research exploring the use of this injection related to Alcohol Use Disorder has utilized short-term, placebo-controlled clinical trials. These studies examined outcomes such as the change in the frequency of heavy drinking, time to the first heavy drinking event, and the proportion of participants who maintained complete abstinence. The populations studied for AUD were primarily adult outpatients. The findings describe patterns observed in the studies where measurements of heavy drinking days differed for participants receiving the injection compared to placebo. Studies typically reported how symptoms evolved over 6 months (24 weeks).

---

Evidence for Use in Opioid Use Disorder (OUD)

The evidence base for OUD includes both placebo-controlled RCTs and trials that explored comparisons to other existing medications. These studies focused on participants who were opioid-free for at least one week following detoxification. Research examined outcomes like confirmed opioid abstinence, treatment retention, and time to relapse. Pivotal trials report how symptoms evolved where the proportion of participants with confirmed abstinence differed compared to the placebo group. A key limitation is that the treatment requires a mandatory opioid-free period for successful induction, which was associated with patient withdrawal from the study prior to receiving the injection.

---

Evidence in Special Populations

Research has explored the use of the injection in high-risk groups, including those involved in the criminal justice system and populations with co-occurring infections (e.g., HIV/Hepatitis C). However, Data for certain groups remain limited. Evidence is limited regarding the use of the injection in adolescents or older adults (age 65 and over), as these groups were not broadly evaluated in the primary clinical trials.

---

What Is Still Uncertain About Vivitrol Injection

Key areas where certainty remains low include the long-term patterns of use beyond the typical 6-month study window, as follow-up durations were limited. Comparative evidence is lacking for certain patient subgroups, and the results apply only to the populations studied. This is why research is ongoing in this area.

Common questions about Vivitrol injection (FAQ)

---

Q: What is the main difference between Vivitrol and oral naltrexone?

A: Vivitrol is an extended-release, once-monthly injection, while the same active ingredient is also available in a daily tablet form. Official documents indicate that the specialized injection formulation provides a sustained level of the medicine in the body for approximately four weeks. This long-acting approach is the primary difference and is intended to support patient compliance over the course of treatment.

---

Q: Why is Vivitrol given as an injection instead of a pill?

A: The medication is designed as an extended-release suspension, which allows a single dose to provide pharmacological coverage for about four weeks. This controlled-release formulation ensures a sustained level of the medicine, which is why it is administered as a monthly deep intramuscular injection by a healthcare professional.

---

Q: What should a person do if they notice swelling or pain where they got the shot?

A: Official product information states that severe injection site reactions are possible, including intense pain, swelling, lumps, or a dark scab. If a patient experiences a concerning reaction that gets worse or fails to improve within two weeks, the regulatory information suggests contacting a healthcare provider.

---

Q: Does Vivitrol help with the general cravings for alcohol or opioids?

A: Studies and official information indicate that Vivitrol helps to reduce self-reported cravings associated with both alcohol and opioid dependence. The medicine works by blocking specific opioid receptors in the brain, which are part of the reward pathways implicated in these conditions.

---

Q: Can people taking Vivitrol still drive or operate heavy machinery?

A: The regulatory patient guide contains a warning that the medicine may cause dizziness and sleepiness (somnolence). The guide includes warnings against driving, operating machinery, or participating in hazardous activities until the effect of the medication is known.

---

Q: Do clinical trials show Vivitrol is effective for both opioid and alcohol use?

A: Regulatory documents summarize clinical trials that examined Vivitrol's use for both opioid dependence and alcohol dependence. For opioid dependence, studies monitored confirmed abstinence and relapse prevention, while for alcohol dependence, outcomes included the reduction in heavy drinking days compared to placebo.

---

Q: Is it safe to take over-the-counter cold medicines while receiving Vivitrol?

A: Official information states that Vivitrol blocks the effects of all opioid-containing medicines, including certain remedies for cough, cold, and diarrhea. The regulatory text states that patients should inform their healthcare provider about all prescription and non-prescription medicines before taking them.

---

Q: Is Vivitrol a maintenance treatment, or is it used only short-term?

A: Vivitrol is indicated for use in comprehensive treatment programs to prevent relapse in opioid dependence and for the treatment of alcohol dependence. The regulatory label defines the conditions for use but does not specify a maximum duration for how long the medication can be used.

---

Q: Does Vivitrol change a person's mood or personality?

A: The official regulatory label lists new or worsening depression and suicidal thoughts or behaviors as a serious risk associated with the medication. Monitoring for these specific mood changes is described as part of the management during treatment.

---

Q: How does the structure of Vivitrol (extended-release) differ from the daily pill form?

A: Vivitrol is structurally formulated as an extended-release suspension consisting of naltrexone microspheres. This specialized physical structure allows the active ingredient to be released slowly and continuously into the body over the entire four-week period between injections.

---

Q: What kind of medical supervision is needed during treatment with Vivitrol?

A: Since the injection must be prepared and administered by a healthcare professional, treatment requires medical supervision. This supervision includes monitoring for clinically significant risks such as liver problems, severe reactions at the injection site, and new or worsening depression or suicidal thoughts.

---

Q: What are the requirements for a person's medical history to be eligible for Vivitrol?

A: Official regulatory information states that a person must be opioid-free for a minimum period of 7 to 14 days before starting treatment. Other requirements include not having conditions like acute hepatitis or liver failure, or a history of hypersensitivity to the drug or any of its components.

---

Q: Is Vivitrol injection painful, and what can be done about the pain?

A: Injection site pain, tenderness, and swelling are listed as common reported side effects in official documents. The label includes instruction for patients to inform their healthcare provider about any concerning pain or reaction at the injection site that does not begin to improve within two weeks of receiving the shot.

---

Q: Is Vivitrol used for things other than opioid and alcohol dependence?

A: According to the official regulatory documents, Vivitrol is approved only for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. Any other use is not included in the official indications for the medicine.

---

Q: How quickly does the effect of Vivitrol start after getting the shot?

A: Official pharmacokinetic information indicates that the level of the active ingredient, naltrexone, in the blood rises rapidly following administration. The initial concentration peak is described as occurring approximately 2 hours after the deep intramuscular injection.

---

Q: Does Vivitrol affect the way other non-opioid pain medications work?

A: Official interaction studies state that naltrexone metabolism does not rely on the CYP P450 system, which is common to many other drugs. This mechanism suggests that typical interactions with most non-opioid pain medications are not expected.

---

Q: Is it true that Vivitrol makes it impossible to feel the effects of alcohol?

A: The medicine is indicated for alcohol dependence and works by affecting the brain’s mesolimbic reward pathway. Unlike some other alcohol treatments, official information states that Vivitrol does not cause a disulfiram-like reaction (physical sickness) upon alcohol consumption.

---

Q: Does Vivitrol have any known interactions with common antidepressants?

A: The regulatory label confirms that Vivitrol's clearance process does not rely on the Cytochrome P450 (CYP) system. Because many antidepressants rely on the CYP system for metabolism, typical CYP-mediated drug interactions are not anticipated with naltrexone.

---

Q: Is there a risk of becoming dependent on Vivitrol itself?

A: According to regulatory classification, Vivitrol's active ingredient, naltrexone, is non-narcotic and is not listed as a controlled substance. Official information indicates that the medication is not considered habit-forming.

---

Q: What is the longest period of time a person can stay on Vivitrol?

A: Official regulatory documents do not specify a maximum amount of time a person can remain on treatment. The medicine is indicated for relapse prevention, and initial pivotal clinical trials often studied its use over a period of 6 months (24 weeks).

---

Q: What are the most common reasons a doctor would stop giving a patient Vivitrol?

A: Treatment may need to be discontinued by a healthcare professional if the patient develops a serious liver problem (hepatotoxicity), or if a severe injection site reaction occurs that requires surgical intervention. Additionally, the drug may be stopped if the patient experiences new or worsening depression or suicidal thoughts.

---

Q: Are headaches a common reported side effect of the Vivitrol injection?

A: Yes, official regulatory information lists headaches among the common adverse reactions reported by participants during clinical studies of the medicine.

---

Q: Does taking Vivitrol mean a person is cured of dependence?

A: Vivitrol is formally indicated for the prevention of relapse and the treatment of dependence. The regulatory label emphasizes that the medicine must be used as part of a comprehensive management program that also includes counseling and psychosocial support.

---

Q: Are there any studies comparing Vivitrol to non-medication-assisted treatments?

A: Official product information states that Vivitrol is intended to be used as part of a comprehensive management program. This program includes counseling and psychosocial support, indicating that the medicine is not meant to be used in isolation from non-medication-assisted treatments.

---

Q: Can Vivitrol interact with herbal supplements?

A: The patient counseling information states that individuals should notify their healthcare provider about all substances they take. This includes prescription and non-prescription medicines, as well as vitamins and herbal supplements, before starting or continuing treatment.

---

Q: Can a patient stop Vivitrol treatment at any time, or does it need to be tapered?

A: Because Vivitrol is an extended-release injection, it is not stopped by tapering. The medication's blocking effect naturally fades over several weeks after the last dose is administered. Official warnings indicate that sensitivity to opioids may be increased after the blocking effect has fully decreased.

---

Q: Does Vivitrol show up on standard drug screening tests?

A: The active ingredient, naltrexone, and its primary metabolite are detectable in the body. Official information indicates that naltrexone may interfere with certain immunoassay drug screening tests, which can potentially lead to a false-positive result for other substances.

Vivitrol (naltrexone extended-release injectable suspension) requires strict adherence to labeled storage and disposal requirements.

---

Storage Conditions

Temperature Requirements

The entire dose pack must be stored in the refrigerator at a temperature range of 2 C to 8 C (36 F to 46 F). The product must not be frozen and should not be exposed to temperatures above 25 C (77 F). Unrefrigerated storage of the microspheres is permitted for a maximum of 7 days at temperatures not exceeding 25 C. Prior to preparation, the carton must be removed from refrigeration to reach room temperature for approximately 45 minutes.

Protection

The medication must be kept out of reach of children.

---

Disposal Instructions

Used and unused items from the dose pack must be discarded in proper waste containers. All sharps, including needles, must be disposed of in a designated sharps container.